Axillary Hyperhidrosis - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464128 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Axillary Hyperhidrosis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2019, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 2 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Axillary Hyperhidrosis - Overview

Axillary Hyperhidrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axillary Hyperhidrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axillary Hyperhidrosis - Companies Involved in Therapeutics Development

Brickell Biotech Inc

DelNova Inc

Dermata Therapeutics LLC

Dermavant Sciences Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

Medytox Inc

Revance Therapeutics Inc

Axillary Hyperhidrosis - Drug Profiles

(oxybutynin + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrronium tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivobotulinumtoxin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReViVox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sofpironium bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Axillary Hyperhidrosis - Dormant Projects

Axillary Hyperhidrosis - Discontinued Products

Axillary Hyperhidrosis - Product Development Milestones

Featured News & Press Releases

Jul 09, 2019: Dermata Therapeutics announces positive results from a phase 1 clinical trial of DMT410, a new topical delivery mechanism for botulinum toxin

Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis

Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis

Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating

Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis

Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464128 | GMDHC11491IDB

Number of Pages

47

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Data
30-04-2017

$2,500 USD

Published by Global Markets Direct
11-04-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Axillary Hyperhidrosis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.